Furthermore, genetic deletion of SLC7A11 or pharmacological inhibition with sulfasalazine (SAS) selectively killed KRAS mutant cancer cells in vitro and inhibited tumor growth in vivo, suggesting the functionality and specificity of SLC7A11 as a therapeutic target. The gene discussed is SLC7A11; the disease is cancer.